Related Experiment Video
Updated: Jul 23, 2026
Anticancer Metal Complexes: Synthesis and Cytotoxicity Evaluation by the MTT Assay
Published on: November 10, 2013
G2/M-Phase-Inhibitory Mitochondrial-Depolarizing Re(I)/Ru(II)/Ir(III)-2,2'-Bipyrimidine-Based Heterobimetallic
Nilmadhab Roy1, Shanooja Shanavas2, Binoy Kar1
1Department of Chemistry, School of Advanced Sciences, Vellore Institute of Technology, Vellore 632014, Tamilnadu, India.
Abstract:
Triple-negative breast cancer (TNBC) is an extremely vicious subtype of human breast cancer having the worst prognosis along with strong invasive and metastatic competency. Hence, it can easily invade into blood vessels, and presently, no targeted therapeutic approach is available to annihilate this type of cancer. Metal complexes have successfully stepped into the anticancer research and are now being applauded due to their anticancer potency after the discovery of cisplatin. Many of these metal complexes are also well recognized for their activity toward breast cancer. As the TNBC is a very dangerous subtype and has long been a challenging ailment to treat, we have intended to develop a few brand new mixed metallic Ru(II)/Ir(III)/Re(I)-2,2'-bipyrimidine complexes [L'Re2], [L'RuRe], and [L'IrRe] to abate the unbridled proliferation of TNBC cells. The potency of the complexes against TNBC cells has been justified using MDA-MB-468 TNBC cell lines where complex [L'IrRe] has displayed significant potency among all the three complexes with an IC50 value of 24.12 μM. The complex [L'IrRe] has been competent to cause apoptosis of TNBC cells through inhibition of the G2/M phase in the cell cycle in association with a profuse amount of ROS generation and mitochondrial depolarization.
Insights
New metal complexes show promise against triple-negative breast cancer (TNBC). The iridium-containing complex [L'IrRe] effectively inhibited TNBC cell proliferation and induced cell death, offering a potential new therapeutic strategy.
Area of Science:
- Inorganic Chemistry
- Medicinal Chemistry
- Cancer Biology
Background:
- Triple-negative breast cancer (TNBC) is an aggressive subtype with poor prognosis and limited treatment options.
- Metal complexes, inspired by cisplatin, are emerging as potent anticancer agents, including for breast cancer.
- Developing novel targeted therapies for TNBC remains a critical unmet need.
Purpose of the Study:
- To synthesize and evaluate novel mixed metallic Ru(II)/Ir(III)/Re(I)-2,2'-bipyrimidine complexes for their efficacy against TNBC.
- To identify the most potent complex and elucidate its mechanism of action in TNBC cells.
Main Methods:
- Synthesis of three novel mixed metallic complexes: [L'Re2], [L'RuRe], and [L'IrRe].
- In vitro evaluation of antiproliferative activity against MDA-MB-468 TNBC cell lines.
- Assessment of cell cycle progression, apoptosis induction, reactive oxygen species (ROS) generation, and mitochondrial membrane potential.
Main Results:
- Complex [L'IrRe] demonstrated significant antiproliferative potency against TNBC cells with an IC50 value of 24.12 μM.
- [L'IrRe] induced apoptosis in TNBC cells by inhibiting the G2/M phase of the cell cycle.
- The observed anticancer effects were associated with increased ROS production and mitochondrial depolarization.
Conclusions:
- The novel mixed metallic complex [L'IrRe] exhibits promising anticancer activity against triple-negative breast cancer.
- Its mechanism involves cell cycle arrest, apoptosis induction, oxidative stress, and mitochondrial dysfunction.
- This complex represents a potential lead compound for the development of new TNBC therapeutics.
